Opioid Damages and Health Care Costs Recovery Act, 2019, S.O. 2019, c. 17, Sched. 2

Schedule 1

Cite as Opioid Damages and Health Care Costs Recovery Act, 2019, S.O. 2019, c. 17, Sched. 2, Schedule 1 · current to November 11, 2026 · consolidated from June 6, 2024 · read from e-Laws on November 16, 2026

The text

Schedule 1 1 A product that contains any of the following drugs or active ingredients is an opioid product for the purposes of this Act: 1. Anileridine. 2. Buprenorphine, including but not limited to buprenorphine hydrochloride. 3. Butorphanol, including but not limited to butorphanol tartrate. 4. Codeine, except for those products referred to in subsection 36 (1) of the Narcotic Control Regulations (Canada), including but not limited to codeine phosphate. 5. Diacetylmorphine. 6. Fentanyl, including but not limited to fentanyl citrate. 7. Hydrocodone, including but not limited to hydrocodone bitartrate. 8. Hydromorphone, including but not limited to hydromorphone hydrochloride. 9. Levorphanol. 10. Meperidine, including but not limited to meperidine hydrochloride. 11. Methadone, including but not limited to methadone hydrochloride. 12. Morphine, including but not limited to morphine hydrochloride and morphine sulfate. 13. Nalbuphine. 14. Normethadone, including but not limited to normethadone hydrochloride. 15. Opium, including but not limited to opium and belladonna. 16. Oxycodone, including but not limited to oxycodone hydrochloride. 17. Oxymorphone, including but not limited to oxymorphone hydrochloride. 18. Pentazocine, including but not limited to pentazocine hydrochloride and pentazocine lactate. 19. Propoxyphene. 20. Remifentanil. 21. Sufentanil. 22. Tapentadol, including but not limited to tapentadol hydrochloride. 23. Tramadol, including but not limited to tramadol hydrochloride.
Read the Opioid Damages and Health Care Costs Recovery Act, 2019 on e-Laws ↗